University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Updates
HIV Meds Updates
Related Resources
ARV Profiles
ARV Charts & Tables
Drug Interactions
Latest Updates
Long-Acting Injectable ART: Cabotegravir + Rilpivirine, posted April 24, 2019.
PrEP: TDF/FTC vs TAF/FTC in MSM, posted April 24, 2019.
FDA Approves 2-Drug Combination of Dolutegravir and Lamivudine, posted April 15, 2019.
Rapid ART Start, posted October 16, 2018.
Doravirine--New NNRTI Approved by FDA, posted October 10, 2018.
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects, posted September 24, 2018.
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy, posted September 24, 2018.
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women, posted September 24, 2018.
U=U in PARTNER2 Study of MSM, posted August 20, 2018.
Dolutegravir + 3TC in Initial Therapy, posted August 20, 2018.
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study, posted August 20, 2018.
Possible Safety Issue with Dolutegravir in Pregnancy: Reports of Neural Tube Defects, posted May 23, 2018.
Bictegravir Approved for Initial ART, in Combination with TAF/FTC, posted April 11, 2018.
Bictegravir/TAF/FTC for Women, posted April 11, 2018.
Immediate ART Initiation Improves Time to Viral Suppression, posted April 11, 2018.
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir), posted April 11, 2018.
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study, posted April 11, 2018.
Naltrexone Improves Virologic Suppression, posted April 11, 2018.
Ibalizumab Approved for Persons with Multidrug Resistant HIV, posted April 11, 2018.
Undetectable=Untransmittable: Effective HIV Treatment Prevents HIV Transmission, posted December 14, 2017.
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen, posted September 28, 2017.
Bictegravir in Initial Therapy, posted September 28, 2017.
Doravirine in Initial Therapy: DRIVE-AHEAD Study, posted September 28, 2017.
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment, posted April 14, 2017.
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison, posted April 14, 2017.
CROI 2017: Dolutegravir in 2-Drug Simplification Studies, posted April 14, 2017.
CROI 2017: Failure of Dolutegravir Monotherapy, posted April 14, 2017.
PrEP Uptake by Sex, Race, and Age, posted September 27, 2016.
RAPID: Immediate ART Initiation, posted September 27, 2016.
Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk; also a Word on HPTN 052, posted September 27, 2016.
ART in Acute HIV--Decreasing HIV DNA, posted September 27, 2016.
Improvements in ART and Viral Suppression Rates in the United States, posted September 27, 2016.
HIV in Indiana, posted September 27, 2016.
PrEP: Bone Density Improves after Stopping TDF/FTC, posted May 3, 2016.
Use of Dolutegravir in Dialysis, posted May 3, 2016.
TAF/FTC Coformulation Approved, posted April 26, 2016.
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy, posted April 11, 2016.
Switching from TDF/FTC to TAF/FTC, posted March 17, 2016.
Tissue Levels of TAF: Too Low for PrEP?, posted March 17, 2016.
FDA Approves New TAF-Containing Analogue of Complera; Complera Approved for Pediatrics, posted March 17, 2016.